Lupus‐like reaction to interferon at the injection site: report of five cases

Arrue, I.; Sáiz, Ana; Ortiz‐Romero, Pablo L.; Rodríguez‐Peralto, José Luis

doi:10.1111/j.1600-0560.2007.00715.x

Cited by 55 publications

(41 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lupus-like reactions were described in four MS patients who were treated with IFN-β-1b. [93][94][95] Cutaneous events with an inflammatory pathogenesis that were described only once in association with DMTs include dermatomyositis, erythema nodosum, scleromyxedema, lupus erythematosus profundus, vitiligo, and Jessner-Kanof benign lymphocytic infiltrate. [96][97][98][99][100][101] …”

Section: Immune-mediated Cutaneous Adverse Eventsmentioning

confidence: 99%

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

et al. 2012

View full text Add to dashboard Cite

Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases without applying restrictions in study design, language, or publishing date. Eligible for inclusion were articles describing any skin reaction related to DMTs in MS patients. Selection of articles and data extraction were performed by two authors independently. One hundred and six articles were included, of which 41 (39%) were randomized controlled trials or cohort studies reporting incidences of mainly local injection-site reactions. A large number of patients had experienced some form of localized injection-site reaction: up to 90% for those using subcutaneous formulations and up to 33% for those using an intramuscular formulation. Sixty-five case-reports involving 106 MS patients described a wide spectrum of cutaneous adverse events, the most frequently reported being lipoatrophy, cutaneous necrosis and ulcers, and various immune-mediated inflammatory skin diseases. DMTs for MS are frequently associated with local injection-site reactions and a wide spectrum of generalized cutaneous adverse events, in particular, the subcutaneous formulations. Although some of the skin reactions may be severe and persistent, most of them are mild and do not require cessation of DMT.

show abstract

Section: Immune-mediated Cutaneous Adverse Eventsmentioning

confidence: 99%

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…At the site of injections a pruritic erythematous patch was seen in a few patients, in 2 of them as a vesicobullous eruption. Others reported more frequent localized reactions with various presentations [5,6,7]. These changes were managed by the use of emollients and topical corticosteroids.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin

Patrk¹,

Morović²,

Markulin³

et al. 2014

Dermatology

View full text Add to dashboard Cite

Background/Objective: Peginterferon alfa and ribavirin could cause various cutaneous reactions. Treatment-related cutaneous reactions are common, and treatable complications can contribute to the treatment discontinuation. Methods: We performed a 6-year prospective study of cutaneous reactions in 271 patients with chronic hepatitis C treated with peginterferon and ribavirin. Results: Cutaneous reactions of mild to moderate degree were seen in 36 (13.3%) patients: localized cutaneous reactions in 7 (2.6%) patients, generalized reactions - pruritus, skin xerosis and eczematous changes - in 28 (10.3%) patients, alopecia in 11 (4.1%) patients; exacerbation of lichen planus was seen in 1 patient. Conclusion: The study showed a relatively low prevalence of cutaneous reactions without the need for discontinuation of any of the drugs used. These reactions correlated only with the age of the patients and treatment duration. This finding is of particular importance with regard to the recently introduced direct-acting antivirals in the treatment of hepatitis C virus infection, which can cause a very severe form of cutaneous reactions.

show abstract

“…127 Recently, 5 cases of cutaneous reactions at the injection site of interferon beta-1b with histologic findings mimicking CLE were reported. 128 Side effects of interferon therapy include flu-like syndrome, headache, fever, depression, and hair loss.…”

Section: Interferon Alfamentioning

confidence: 99%